Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: Daiichi Sankyo Korea and AstraZeneca Korea received approval for two additional Enhertu indications: 1L HER2-positive metastatic Breast cancer and 2L HER2-positive metastatic Gastric cancer Enhertu has secured […]
Weekly Digest – May 2026 Weekly Digest – May 2026 06 May 2026: HLX43 received PMDA acknowledgment to initiate a global Phase 2/3 trial in squamous Non-Small Cell Lung Cancer Henlius has achieved a key milestone for its anti-PD-L1 ADC […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: InnoCare Pharma’s independently developed CDH17-targeted ADC innovative drug ICP B208 has been approved for clinical trials InnoCare Pharma has expanded its ADC pipeline after receiving National Medical […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: ArriVent announces IND clearance for novel tetravalent MUC16/NaPi2b targeting ADC ARR-002 with initial focus in Ovarian and Endometrial cancers ArriVent BioPharma has received IND clearance for ARR-002, […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: Bristol Myers Squibb licenses Antibody-Drug Conjugate technology from Lonza Bristol Myers Squibb has expanded its ADC strategy through an exclusive licensing agreement with Lonza, gaining access to […]
Weekly Digest – May 2026 Weekly Digest – May 2026 06 May 2026: Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC program Waiv, formerly known as Owkin Dx, has entered a new collaboration with Daiichi Sankyo […]
